OZETTE

Serial Number 97977789
Registration 7393452
700

Registration Progress

Application Filed
Apr 21, 2022
Under Examination
Aug 22, 2023
Approved for Publication
Jun 27, 2023
Published for Opposition
Jun 27, 2023
Registered
May 21, 2024

Trademark Image

OZETTE

Basic Information

Serial Number
97977789
Registration Number
7393452
Filing Date
April 21, 2022
Registration Date
May 21, 2024
Published for Opposition
June 27, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
May 21, 2024
Registration
Registered
Classes
042 044

Rights Holder

Ozette Technologies, Inc.

03
Address
1522 Western Ave, Ste 24206
Seattle, WA 98101

Ownership History

Ozette Technologies, Inc.

Original Applicant
03
Seattle, WA

Ozette Technologies, Inc.

Owner at Publication
03
Seattle, WA

Ozette Technologies, Inc.

Original Registrant
03
Seattle, WA

Legal Representation

Attorney
Chelsea E. Carbone

Application History

38 events
Date Code Type Description Documents
Aug 11, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 11, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Aug 11, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Aug 11, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 11, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
May 21, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
May 21, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 17, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Apr 16, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Mar 23, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 22, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Mar 22, 2024 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Mar 22, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 29, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 6, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Feb 6, 2024 IUAF S USE AMENDMENT FILED Loading...
Feb 6, 2024 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Feb 6, 2024 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Feb 5, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 5, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 22, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 27, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 27, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 7, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 25, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 25, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 25, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
May 25, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
May 25, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
May 24, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 22, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 22, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 23, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 23, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 23, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 8, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 27, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 25, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for analyzing immune data for the purposes of medical research, diagnosis, and treatment; providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for analyzing immune data for the purposes of identifying, prescribing and monitoring medications; providing temporary use of non-downloadable computer software using artificial intelligence (AI) and machine learning for diagnosing, monitoring and treating diseases and disorders, namely, infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders; scientific research and development; pharmaceutical research and development; medical research; medical and pharmaceutical research services; cloud hosting provider services for storing, analyzing and sharing biological information; providing an online network environment service featuring technology that enables users to store, analyze and share data in the fields of life science; technical support services, namely, infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the fields of life science; product design and development of laboratory apparatus and instruments and design and development of computer software systems for use in analysis of biomolecules; installation and maintenance of computer software and software databases used in the field of analysis of biomolecules; consultancy, information, and advisory services in the field of medical research analysis of biomolecules, diseases, disorders, and treatment efficacy; product development, namely, developing equipment for use in preparing, detecting, sequencing, quantifying, and analyzing proteins and other biological molecules, and automated laboratory equipment and systems, and computer systems for collecting, storing, analyzing, and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data to the order and specification of others, all the foregoing in the fields of scientific and clinical research; medical and scientific research in the fields of vaccines, pharmaceuticals, biologics, vaccines, adjuvants, adjuvant formulations, biologic formulations, drug delivery, diagnostics, and medical therapeutics; product research and development in the fields of pharmaceuticals, vaccines, diagnostics, adjuvants, adjuvant formulations, biologic formulations, and drug delivery; custom design and development of chemical reagents and biochemical assays; testing of pharmaceuticals; scientific laboratory services; computer and scientific research in the field of artificial intelligence (AI) and machine learning for analysis of immune data, disease states, and treatment response
First Use Anywhere: 20230500
First Use in Commerce: 20230500
Class 044
Medical testing and reporting for diagnostic or treatment purposes; consultancy, information, and advisory services in the field of medical treatment of infectious disease, cancer, autoimmune disorders, cardiovascular disease, and neurological disorders
First Use Anywhere: 20230500
First Use in Commerce: 20230500

Classification

International Classes
042 044